Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Brain Imaging Studies Reveal Neurobiology of Eating Disorders

By BiotechDaily International staff writers
Posted on 30 Apr 2013
Current treatments for bulimia nervosa and anorexia are frequently inadequate and ineffective. Patients have a tendency to relapse, become chronically ill, and have a higher risk of dying.

“A major reason contributing to the difficulty in developing new treatments for these disorders is our limited understanding of how brain function may contribute to eating disorder symptoms,” said Walter H. Kaye, MD, professor of psychiatry and director of the Eating Disorder Treatment and Research Program at the University of California (UC), San Diego School of Medicine (USA).

Recently, Dr. Kaye and colleagues reported the situation is changing. Cutting-edge brain imaging technologies, specifically functional magnetic resonance imaging (fMRI), supported by grants from the National Institute of Mental Health (Bethesda, MD, USA), are beginning to be used to study and improve eating disorder treatments. With funding from the Global Foundation for Eating Disorders (GFED; New York, NY, USA), a group that promotes eating disorder (ED) research and improved treatments, the UC San Diego Eating Disorders Center for Treatment and Research has launched a new initiative to create more effective ED therapies based upon brain imaging studies.

“Brain imaging research has allowed for a shift from simply describing a symptom to understanding the cause of a symptom,” said Dr. Kaye. “In the case of anorexia nervosa, imaging studies have helped us understand why people avoid eating and food and develop treatments that address the cause of the problem rather than secondary behaviors or symptoms. This is an important shift in the world of psychiatry similar to what revolutionized medical care decades ago. Today, if you show up at the doctor’s office with a bad cough, he or she might run diagnostics to determine whether the cough was bacterial or viral in order to administer the appropriate treatment. Similarly, the more we understand the specific causes of eating disorders, the more effective, and targeted our treatments can become.”

The UC San Diego program, under the directorship of Dr. Kaye, Kerri Boutelle, PhD, associate professor of pediatrics and psychiatry, Leslie Karwoski Anderson, PhD, clinical assistant professor of psychiatry and GFED scholars Stephanie Knatz and June Liang, is developing an imaging-based treatment strategy exclusively to handle the neurobiology of anorexia nervosa, in which patients obsess about being or becoming overweight. To prevent weight gain or lose weight, people with anorexia nervosa typical may starve themselves or exercise excessively.

Dr. Kaye reported that one neurobiologic target of anorexia and other eating disorders is anxiety. Most people get short-tempered when they do not eat and experience eating as both a reward and pleasant experience. Contrarily, anorexic individuals frequently feel severe anxiety when eating food, or even just anticipating eating, which results in severely reducing their food intake as a means of reducing their feelings of anxiety. “Recent imaging research has uncovered specific alterations in the brain associated with this link between food and anxiety in anorexic individuals,” said Dr. Kaye. “This finding is important because it helps explain the of cause food restriction, the most critical and dangerous behavior in anorexia.”

The UC San Diego researchers have used the new data to create new treatment strategies, including psychoeducation, i.e., teaching patients why symptoms occur and how to more effectively cope. “Many patients have described finally feeling a wave of relief after learning that the anxiety they experience is not their fault, but partly due to how their brain is responding to food,” stated Dr. Kaye. “Understanding why their eating disorder is driving them to restrict allows them to better target their anxiety around meals. Strategies such as developing routines before meals have shown promise in reducing the anticipatory anxiety leading up to meals and food restriction.”

Dr. Kaye noted that the brain-based therapy also benefits families of patients with eating disorders. “Through a better understanding of their family member’s eating disorder and its causes, family members have found comfort and hope with a ‘road map’ guiding them through the recovery.”

Related Links:
University of California, San Diego School of Medicine


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.